logo-loader
viewZelda Therapeutics Ltd

Zelda Therapeutics to outline cannabinoid-based strategy at Proactive CEO Sessions

The company was recently awarded a patent for a novel prognostic biomarker for breast cancer.

Zelda managing director Dr Richard Hopkins
Zelda managing director Dr Richard Hopkins

Zelda Therapeutics Ltd (ASX:ZLD) is developing a range of cannabinoid-based formulations for the treatment of a variety of medical conditions, with a focus on cancer therapies.

The company is undertaking:

• A human clinical trial program focused on insomnia, autism and opioid reduction with activities in Australia and the USA.

• A pre-clinical research program examining the effect of cannabinoids in breast, brain and pancreatic cancer as well as research examining the potential for cannabinoids to treat diabetes-associated cognitive decline.

Zelda managing director Dr Richard Hopkins will present to investors at the Sydney investor event on Monday, May 13 and at the Melbourne event on Tuesday, May 14.

Range of commercialisation opportunities

Zelda’s recent developments include a heads of agreement (HoA) with medicinal cannabis company Ilera Healthcare to explore collaborative opportunities and being granted a new patent covering a novel method to predict patient disease-free survival.

The range of commercialisation opportunities with US-based Ilera include licensing of Zelda products, co-development and data sharing.

READ: Zelda Therapeutics secures patent to detect breast cancer

Zelda’s Australian patent details a method for detecting levels of expression of a novel receptor complex containing proteins HER2 and CB2.

HER2 is a recognised marker of aggressive breast cancer while CB2 is a key receptor in the endocannabinoid system.

Register for the CEO Sessions today

Sydney details, Monday, May 13, 2019

Melbourne details, Tuesday, May 14, 2019

Also featuring at both sessions will be Xanadu Mines Ltd (ASX:XAM), Infinity Lithium Ltd (ASX:INF), Oventus Medical Ltd (ASX:OVN and Invitrocue Ltd (ASX:IVQ).

Quick facts: Zelda Therapeutics Ltd

Price: 0.067 AUD

ASX:ZLD
Market: ASX
Market Cap: $50.84 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Zelda Therapeutics Ltd named herein, including the promotion by the Company of Zelda Therapeutics Ltd in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Ilera Healthcare deal is 'one piece of the puzzle' for Zelda Therapeutics in...

Zelda Therapeutics Ltd (ASX:ZLD, OTCBB:ZLDAF) managing director Dr Richard Hopkins speaks to Proactive Investors about the medical cannabis researcher's binding heads of agreement (HoA) with US-based medicinal cannabis company Ilera Healthcare LLC. The deal complements a number of...

on 03/12/2019

2 min read